Abstract
The therapeutic use of an antioxidant complex containing superoxide dismutase and catalase has been proposed for the treatment of several diseases in which reactive oxygen species have an important role. Although superoxide dismutase for human use is commercially available, methods for the production of catalase for human use have not been described. An industrial process was developed for the purification of catalase for human use as a by-product of albumin production from human placenta, comprising two parts: (1) albumin and catalase co-purification steps, including blood extraction from ground placentas, precipitation of haemoglobin with ethanol/chloroform, concentration/diafiltration by tangential filtration and anionic chromatography, by which non-adsorbed catalase was separated from albumin; and (2) catalase purification steps after albumin separation, including a second anionic chromatography step and dye-affinity chromatography. This method provided a final recovery of 27% (70-100% in each step) with 670-fold purification of catalase (85% pure) and a specific activity of 49000 units/mg, which is higher than that of commercially available human catalase. This process permits the co-purification of catalase and albumin and can easily be scaled up.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
